Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 30, 2020

Fujifilm Irvine Scientific Becomes Worldwide Distributor of Cellnest

Cellnest will join Fujifilm Irvine Scientific’s PRIME-XV portfolio which consists of xeno-free and chemically defined media for stem cell culture.

Fujifilm Irvine Scientific announced on Sept. 29, 2020 that it has become a worldwide distributor of cellnest, a recombinant peptide attachment substrate for optimal adhesion and proliferation of stem cells in chemically defined, animal-component-free conditions.

Designed and manufactured by Fujifilm Corporation, cellnest can work in conjunction with any adherent cell type that attaches to the Arg-Gly-Asp (RGD) domain, an amino acid sequence within the extracellular matrix protein fibronectin that facilitates cell binding, a company press release said. Cellnest will join Fujifilm Irvine Scientific’s PRIME-XV portfolio which consists of xeno-free and chemically defined media for stem cell culture.

“We are dedicated to accelerating the development and introduction of new offerings, including cellnest, to support our partners in advancing cell and gene therapy research,” said Yutaka Yamaguchi, general manager, Life Science Strategic Business Office, Fujifilm Holdings America Corporation, and chairman and CEO, Fujifilm Irvine Scientific, in the press release. “Leveraging the collective expertise and capabilities of our resources within the network of Fujifilm life science companies, enables us to provide innovative solutions for our partners, from discovery through to commercialization.”

Source: Fujifilm Irvine Scientific​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.